Retrospective Comparative Study of Absolute Ethanol with N-Butyl-2-Cyanoacrylate in Percutaneous Portal Vein Embolization.
This study compared the efficacy of absolute ethanol with that of N-butyl-2-cyanoacrylate (NBCA) in portal vein embolization (PVE) before partial hepatectomy. Between January 2012 and February 2016, 61 patients (43 men, 18 women; median; 69 years of age) underwent PVE using absolute ethanol (January 2012 to January 2014; n = 27) or NBCA (February 2014 to February 2016; n = 34). The primary endpoint was increase in the nonembolized liver volume (NELV)-to-total functional liver volume (TFLV) ratio, and the secondary endpoints were changes in embolized liver volume (ELV) and NELV, changes in laboratory data, and adverse events. The increase in the NELV/TFLV ratio was significantly higher in the ethanol group than in the NBCA group (13.0% vs. 9.5%, respectively; P = 0.003). The decrease in ELV was significantly greater in the ethanol group (-191.9 vs. -99.2 mL, respectively; P = 0.001). The increase in NELV did not differ significantly (129.4 vs. 116.0 mL, respectively; P = 0.316). In the ethanol group, grade 3-4 transient elevation of aspartate aminotransferase and alanine aminotransferase occurred in 22 patients (81.5%) and 22 patients (81.5%) patients, respectively, whereas it occurred in 1 patient (3.0%) and 1 patient (3.0%), respectively, in the NBCA group. One patient in the ethanol group (3.7%) showed grade 2 hepatic necrosis, and 2 patients with grade 3 subcapsular biloma (5.9%) and 1 with grade 3 liver abscess (2.9%) occurred in the NBCA group (P = 0.696). PVE with ethanol conferred greater increase in the NELV/TFLV ratio than NBCA due to its severe atrophic effect in ELV, but no significant differences in NELV increase were found.